New insights in treatment of NSCLC adenocarcinoma patients after first line therapy

Date: Saturday 21 May 2016
Venue: Arianelaan 16 – 1200 Brussel
Registration: Registration is free of charge.
Route: After registration you will receive a confirmation with route description

Programma

Chair: Prof. Karim Vermaelen, Ghent University

09:00 Welcome – light breakfast

09:30 Introduction

09:45 The role of angiogenesis in lung cancer and the place of nintedanib in the lung cancer treatment
Prof. Peter Carmeliet, KU Leuven

10:30 The LUME-Lung 1 trial in the context of the evolving landscape
Dr. Anders Mellemgaard, Herlev University Hospital, Copenhagen

11:00 Patient cases
• 1st line chemo non responders or fast progressors
• 1st line chemo responders and slow progressors
Panel: Prof. Vermaelen, Prof. Mellemgaard & Prof. Carmeliet

12:00 Lunch sandwiches

Downloads

• Announcement